These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19554084)

  • 21. Has oseltamivir been shown to be effective for treatment of H5N1 influenza?
    Couch RB; Davis BR
    J Infect Dis; 2010 Oct; 202(8):1149-51. PubMed ID: 20831386
    [No Abstract]   [Full Text] [Related]  

  • 22. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
    Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
    Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Countermeasures for newly-emerging influenza].
    Sugaya N
    Nihon Naika Gakkai Zasshi; 2007 Nov; 96(11):2393-9. PubMed ID: 18069288
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment options for H5N1: lessons learned from the H1N1 pandemic.
    Reece PA
    Postgrad Med; 2010 Sep; 122(5):134-41. PubMed ID: 20861597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets.
    van der Vries E; Stittelaar KJ; van Amerongen G; Veldhuis Kroeze EJ; de Waal L; Fraaij PL; Meesters RJ; Luider TM; van der Nagel B; Koch B; Vulto AG; Schutten M; Osterhaus AD
    PLoS Pathog; 2013; 9(5):e1003343. PubMed ID: 23717200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.
    Lu Y; Jiang T
    Protein Cell; 2013 May; 4(5):356-63. PubMed ID: 23589018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avian influenza. WHO proposes plan to stop pandemic in its tracks.
    Normile D
    Science; 2006 Jan; 311(5759):315-6. PubMed ID: 16424302
    [No Abstract]   [Full Text] [Related]  

  • 29. [The new pandemic influenza A/H1N1. Antiviral agents for the initial stage--vaccine reduces the effects in the long run].
    Uhnoo I; Bergquist C
    Lakartidningen; 2009 Jul 8-21; 106(28-29):1814-9. PubMed ID: 19685621
    [No Abstract]   [Full Text] [Related]  

  • 30. Influenza virus resistance to antiviral agents: a plea for rational use.
    Poland GA; Jacobson RM; Ovsyannikova IG
    Clin Infect Dis; 2009 May; 48(9):1254-6. PubMed ID: 19323631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection.
    Kang SJ; Park KH; Kee SJ; Shin JH; Jung SI; Kwon YS; Jang HC
    Jpn J Infect Dis; 2013; 66(5):425-7. PubMed ID: 24047743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.
    Schünemann HJ; Hill SR; Kakad M; Bellamy R; Uyeki TM; Hayden FG; Yazdanpanah Y; Beigel J; Chotpitayasunondh T; Del Mar C; Farrar J; Tran TH; Ozbay B; Sugaya N; Fukuda K; Shindo N; Stockman L; Vist GE; Croisier A; Nagjdaliyev A; Roth C; Thomson G; Zucker H; Oxman AD;
    Lancet Infect Dis; 2007 Jan; 7(1):21-31. PubMed ID: 17182341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial.
    South East Asia Infectious Disease Clinical Research Network
    BMJ; 2013 May; 346():f3039. PubMed ID: 23723457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in and shortcomings of drug stockpiling, vaccine development and related policies during outbreaks of avian influenza A H5N1, H1N1, and H7N9 among humans.
    Mei L; Tang Q; Cui YM; Tobe RG; Selotlegeng L; Ali AH; Xu LZ
    Drug Discov Ther; 2013 Jun; 7(3):95-100. PubMed ID: 23917856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses.
    Dharan NJ; Beekmann SE; Fiore A; Finelli L; Uyeki TM; Polgreen PM; Fry AM
    Antiviral Res; 2010 Nov; 88(2):182-6. PubMed ID: 20739002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oseltamivir dosing for influenza infection in premature neonates.
    Acosta EP; Jester P; Gal P; Wimmer J; Wade J; Whitley RJ; Kimberlin DW;
    J Infect Dis; 2010 Aug; 202(4):563-6. PubMed ID: 20594104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H5N1 virus resistant to oseltamivir isolated from Vietnamese patient.
    ECDC Influenza Team
    Euro Surveill; 2005 Oct; 10(10):E051020.2. PubMed ID: 16790886
    [No Abstract]   [Full Text] [Related]  

  • 38. Keeping alert to changes during the pandemic.
    Thompson C; Rolls S
    Nurs N Z; 2009 Aug; 15(7):30. PubMed ID: 19785327
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiviral therapy and prophylaxis for influenza in children.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2007 Apr; 119(4):852-60. PubMed ID: 17403862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.